Compare iShares Bitcoin Trust (IBIT) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Bitcoin Trust vs Tango Therapeutics Inc. — how do they compare? iShares Bitcoin Trust trades at $45.94 (market cap $66.43B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.75B). The key difference: iShares Bitcoin Trust is far larger — about 17.7× Tango Therapeutics Inc.'s market cap, and Tango Therapeutics Inc. is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Bitcoin Trust for 42 Days and Tango Therapeutics Inc. for 0 Days on average.
| IBIT | TNGX | |
|---|---|---|
Market Cap | $66.43B | $3.75B |
Volume | 28,050,093 | 9,619,106 |
Sector | Crypto-linked | Health |
52-Week High | $65.28 | $32.90 |
52-Week Low | $33.29 | $7.50 |
Typical Hold Time | 42 Days | 0 Days |
Enterprise Value | — | $2.77B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IBIT trades at $47.13, up 0.58% with neutral technical signals overall. The stock shows bullish moving average momentum but mixed oscillators, with key support at $46 and resistance at $48. Recent institutional inflows and positive ETF performance highlight growing investor interest in BlackRock's Bitcoin trust vehicle, though financial ratios remain undisclosed in current filings.
Outlook remains cautiously optimistic given strong institutional inflows and market positioning. Key risks include regulatory uncertainty and Bitcoin price volatility affecting the trust's underlying value. Analyst sentiment appears balanced with technical indicators suggesting near-term consolidation around current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
